US3593854A - Blood treating and filtering apparatus - Google Patents

Blood treating and filtering apparatus Download PDF

Info

Publication number
US3593854A
US3593854A US882663A US3593854DA US3593854A US 3593854 A US3593854 A US 3593854A US 882663 A US882663 A US 882663A US 3593854D A US3593854D A US 3593854DA US 3593854 A US3593854 A US 3593854A
Authority
US
United States
Prior art keywords
blood
mat
filter
upstream
downstream
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US882663A
Inventor
Roy Laver Swank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PIONEER VIGGO Inc
Terumo BCT Inc
Original Assignee
Roy Laver Swank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roy Laver Swank filed Critical Roy Laver Swank
Application granted granted Critical
Publication of US3593854A publication Critical patent/US3593854A/en
Assigned to COBE LABORATORIES, INC. reassignment COBE LABORATORIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BOC GROUP, INC. THE A CORP. OF DE
Assigned to PIONEER VIGGO INC. reassignment PIONEER VIGGO INC. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: SWANK, ROY L.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D35/00Filtering devices having features not specifically covered by groups B01D24/00 - B01D33/00, or for applications not specifically covered by groups B01D24/00 - B01D33/00; Auxiliary devices for filtration; Filter housing constructions
    • B01D35/14Safety devices specially adapted for filtration; Devices for indicating clogging
    • B01D35/153Anti-leakage or anti-return valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/165Filtering accessories, e.g. blood filters, filters for infusion liquids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621Extra-corporeal blood circuits
    • A61M1/3627Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
    • A61M1/3633Blood component filters, e.g. leukocyte filters

Definitions

  • Farley- ABSTRACT Stored human blood is treated preliminary to blood transfusions by passing it through a mat of glass wool or other fibrous material which removes from the blood the storage-generated platelet leukocyte aggregates present therein. It is filtered during open heart surgery by passing it through the same material for removal of aggregates and leukocytes and separation of entrained air.
  • PATENTEB JULZO 1911 SHEU 1 BF 2 QE EL Z 3352c o o. 3 on ow on 3 o ow on Ov On On INVENTOR. ROY LAVER SWANK ATTY.
  • blood bank blood This is prepared by withdrawing blood from donors, adding heparin or other preservative, and then storing the blood under carefully controlled conditions until its use is required.
  • Another object is the provision of a continuous, high capacity, blood filter which contemporaneously filters and deaerates the blood.
  • FIG. 1 is a longitudinal sectional view of the herein described blood treating apparatus, as used in transfusing blood;
  • FIGS. 2 and 3 are plan views of support elements employed in the apparatus of FIG. 1;
  • FIGS. 4 and S are graphs illustrating the effect of fiber diameter and filter density on the performance of filters contained in the apparatus.
  • FIGS.'6, 7 and 8 are sectional, exploded and schematic views illustrating respectively, the construction and application of a modified form of the apparatus, as used in heart surgery.
  • the present invention provides an efficient method and apparatus for accomplishing the removal of such components.
  • FIGS. l3 illustrate apparatus for use particularly in transfusions.
  • the apparatus comprises a tube 10 which may be made of rigid material such as glass, but which preferably is made of a nonpyrogenic, sterilizable, resilient material such as polyethylene plastic.
  • a tube 10 which may be made of rigid material such as glass, but which preferably is made of a nonpyrogenic, sterilizable, resilient material such as polyethylene plastic.
  • Such material makes of the tube a hand pump so that the flow of blood through the apparatus maybe increased by slowly compressing the tube sidewalls in the manner shown in dotted outline in FIG. I.
  • tube 10 normally is arranged vertically and has at its upper end an inlet port and at its lower end an outlet-port.
  • the inlet port of the tube preferably is fitted with a hollow, penetrating spur 12 adapted to pierce the cap 14 of a bottle 16 of blood bank blood.
  • Spur 12 preferably extends inwardly within tube 10 and accordingly acts as a metering device by which drop flow of blood may be monitored.
  • the open lower end of tube 10 is fitted with a cap 18 having an integral valve chamber 20 and a stub exhaust conduit 22.
  • a ball valve assembly 24 is seated within the valve chamber better to control the flow of blood during pumping of tube 10. The ball. valve assembly may be omitted, however, where the head of blood in container 16 is sufficient to prevent reverse flow.
  • a rubber tube or other conduit 26 is attached to stub conduit 22. It conveys the blood to the patient, usually through an interposed flow valve.
  • Tube 10 thus provides a housing for filter elements which selectively remove the undesirable altered components of the stored blood.
  • an upper support 28 is illustrated in detail in FIG. 2 while lower supports 30, 32 which may be substantially identical, are illustrated in FIG. 3. All three supports may be made from substantially rigid plastic.
  • Support 28 mounts a blood clot filter screen 34 of stainless steel or other suitable material. It has a screen size dimensioned to screen out any clots which may be present in the blood.
  • Support 28 also guides the blood to the central area of the tube To this end it comprises a ring 36 which is glued or otherwise affixed to the inner walls of tube 10 and an inwardly pro jecting, annular flange 38.
  • the latter has inwardly extending projections 40, particularly evident in FIG. 2.
  • Supports 30, 32 serve the function of supporting the filter material.
  • Each comprises a ring 42 mounting a characteristic pattern of crosspieces 44.
  • Ring 42 like ring 36, is glued or otherwise fastened to the inner wall of the tube.
  • the three support rings thus provide three chambers 46, 48, 50 of progressively smaller volume. These chambers contain the filter material determining the desired performance of the filter.
  • Chambers 46, 48 contain the filter material 52 responsible for removing the blood aggregates and the altered leukocytes and platelets.
  • the filter material must adhere these storage-altered components selectively; must permit free passage of the other blood components; must have a large area of absorbing surface; must not be nonpyrogenic; must not pack; must not collapse nor plug; and must not be affected adversely by repeated subjection to heat and chemical sterilization.
  • the filter material is used as filaments or fibers which may be formed into a resilient mat compressible as required to produce passageways or channels of optimum size.
  • the diameter or cross-sectional area of the individual particles of the material is of primary importance in determining its suitability.
  • the material should comprise fibers or filaments having lengths of not less than microns and diameters of less than 60 microns, preferably less than 30 microns.
  • Such fibers are sufficiently large so that they will not pass through the filter and into the bloodstream of the patient. They are sufficiently small in diameter so that the storagealtered aggregates can completely surround them with overlapping portions which stick to each other, anchoring the aggregates to the fibers.
  • Material suitable for the present invention purpose thus are fibrous or filamentous polyester resins (Dacron and kodel), filter polyamide resin (Nylon), filamentous polyacrylic resin (Orlon), glass wool, steel wool, cotton, and cellulose (paper).
  • fibrous or filamentous materials meeting the above noted requirements may also be used.
  • the upstream portion of the filter material should be rather loosely packed to allow penetration of the large aggregates and their distribution through the entire .filter, thus increasing its capacity. Downstream, there should be provided a quantity of the filter material which is relatively closely packed. This provides the large surface area necessary to selectively absorb the storage altered components of smaller size.
  • Chamber 46 and to a certain extent the interior of domeshaped clot filter 34, receive the more loosely packed filter material.
  • the central opening and inwardly directed projections 40 of support 28 allow the filter material to fluff up above the support, without freely escaping from the chamber below.
  • Chamber 48 receives the more tightly packed filter material. In general, it may be packed to advantage from two to four times more densely than the filter material contained in chamber 46, i.e. to a density of from 0.1 to 0.4 grams per cubic centimeter.
  • Chamber 50 receives a sponge filter 54 having for its function preventing fragments of the filer material contained in the superimposed chambers from reaching conduit 26, and hence the blood stream of the patient.
  • the sponge filter preferably has a pore size of 60 to 100 pores per square inch. It preferably comprises porous polyurethane or other porous plastic. In the alternative, it may comprise a stainless steel screen or sponge.
  • the apparatus of FIG. 1 was filled with filter materials of varying identity and cross-sectional dimensions. Blood bank blood outdated by several weeks was gravitated through the apparatus at room temperature.
  • the treated blood then was tested for the presence of residual storage-altered components, i.e. adhesive platelets, and leukocytes and aggregates of the same by passing it through the pressure test apparatus described in the patent of Roy L. Swank, U.S. Pat. No. A 3,266,299, and measuring the developed filtration pressure.
  • the results follow in Table l (defiberized paper) It will be observed from the table and graph that the efficiency of the treatment is afiected markedly by the diameter of the packing fibers. To be effective, the fibers should have diameters of less than 60 microns, preferably less than 30 microns. As the diameter decreases, the efficiency of the altered blood component removal increases dramatically.
  • blood contained in the container 16 passes through hollow spur 12 which meters it dropwise into resiliently collapsible tube 10. There it passes first through clot filter 34, which screens out the clots, and onto flange 38 of support 28, which directs it centrally of the tube.
  • the upper resiliently deformable portion of the tube 10 may be slowly compressed and allowed to re-expand. This pumps the blood through the filter and makes possible rapid transfusion in emergency situations.
  • FIGS. 6, 7 and 8 illustrate apparatus useful for filtering blood during open heart surgery, kidney dialysis procedures, etc.
  • the general arrangement of the various units employed in the system is illustrated particularly in FIG. 8.
  • a conduit may be tied to the superior or inferior vena cava 112 using known techniques.
  • a branch conduit 114 having a suction tip 115 made of stainless steel or other inert material is placed in the chest cavity for removal of accumulated blood.
  • Conduit 110 and 114 merge to form main conduit 116 which transfers the blood to a reservoir 1 18 of suitable capacity.
  • the blood then passes through a first pump 120, an oxygenator 122 and a second pump 124.
  • the latter discharges it into the herein described blood treating and filtering apparatus 126.
  • this apparatus may be located variously in the system to meet the needs of various situations. Typical alternate locations are illustrated in dotted outline.
  • conduit 116 The oxygenated, treated, and filtered blood then continues through conduit 116, the discharge end of which is tied into the femoral or other artery 128.
  • the unit comprises an upstream end piece 130, a downstream end piece 132 and a tubular body 134.
  • End pieces 130, 132 may be made from stainless steel or plastic, while body 134 may be made from transparent plastic or glass.
  • the upstream end piece is provided with a central inlet port 136 with outwardly projecting nipple 138 for attachment of one segment of conduit 116.
  • the downstream end piece 132 is provided with a discharge port 140 communicating with a nipple 142 designed to receive another length of conduit 1 16.
  • upstream and downstream end pieces 130, 132, and body 134 provide a central chamber 144 arranged for horizontal flow of the blood.
  • the chamber is sealed by providing in the inner face of the end piece 130 an annular groove 146 seen clearly in FIG. 7.
  • a similar groove, not visible in the same figure, is present in end piece 132. Seal rings I48, 150 are seated in the grooves.
  • a blood treating and filtering assembly comprising a mat 154 of filter material, a perforated, upstream filter-material retainer 156, a screen 158, and a downstream filter-material retainer 160.
  • Retainers 156, 160 serve to locate filter element 154 centrally in the path of flow of the blood. They may be fabricated from suitable durable inert material such as stainless steel or plastic.
  • Screen 158 serves to screen out pieces of filter material 154 which otherwise might be entrained in the blood. It may be made of fine mesh stainless steel, Nylon or other suitable material.
  • the baffle means prevent channeling of the blood through the central-part of filter 154 and insure that the blood diffuses through the entire filter area, thus insuring efficient filtration.
  • the baffle means comprises a central, unperforated section 156a of perforated retainer 156. This is located directly opposite inlet port 136.
  • the subassembly including elements 154, 156, 158 and 160 are maintained spaced apart from end pieces 130, 132. This provides an infeed recess 144a and an outfeed recess 1 14b.
  • a preferred arrangement comprises forming infeed end plate 130 with a peripheral boss 162 and outfeed end plate 132 with a similar peripheral boss 164. These serve as spacers by providing shoulders against which the margins of retaining plates 156, 160 bear in the final assembly of the apparatus.
  • Recess 144a cooperating with baffle area 156a of retaining plate 156, serves the valuable function of causing distribution of the blood over the entire filter area.
  • Recess l44b at the downstream end of the unit serves the valuable function of providing an air trap which permits removal of entrained air from the blood. Such air, when it reaches the downstream end of the unit, will bubble upwardly to the top of recess 14417. There it passes through a port 166 located at the to of end piece 132. A nipple 168 is received in the port and mounts a valve 170 which may be used to exhaust the air as desirable or necessary.
  • the filter element removes the altered leukocytes and platelets, the leukocyte-platelet aggregates, the fat emboli, the epithelium, the pieces of muscle and suture material, and other debris from the blood. This all is accomplished efficiently, continuously and at a high rate sufiicient to accommodate the needs of open heart surgery techniques.
  • Apparatus for treat, preliminary to medical application, human blood containing platelet-leukocyte aggregates comprising:
  • a first meat of finely subdivided blood-contact material comprising a solid fibrous material the fibers of which are nondegrading to the blood and characterized by the ability selectively to adhere the aggregates
  • a second mat of finely subdivided blood-contact material comprising a solid fibrous material the fibers of which are nondegrading to the blood and characterized by the ability selectively to adhere the aggregates, the second mat having a density greater than the first mat for selectively removing aggregates of smaller size, 4. ownstream from the second mat fiber filter member for filtering from the blood fragments of mat fiber filter material,
  • the apparatus of claim 1 including a. a first perforate support member between the blood clot filter member and the first mat, supporting the blood clot filter member and compressing the first mat, and
  • the blood clot filter member comprises a dome-shaped screen support at its open end on the first support member, the latter having a central opening through which the first mat projects into the spacing defined by the screen.
  • the apparatus of claim 4 including inwardly extending projections on the first support member engaging the first mat to prevent free escape of the latter into the space defined by the screen.
  • valve means adjacent the outlet port operable to prevent lback flow of blood from the outlet port into the vessel.
  • the mat fiber has a diameter not substantially great than about 30 microns, the density of the second mat is about 0 .2 grams per cc. and the density of the first mat is about %--%the density of the second mat.
  • a high volume, continuous blood filter comprising:
  • upstream perforated, filter-material-retaining means locating the filter material in the path of the blood flow
  • air-exhaust port means communicating with the top of the recess for exhausting collected air therefrom.
  • spacing means comprises a peripheral boss on the downstream end piece projecting inward therefrom for abutment by the downstream retaining means.
  • the blood filter of claim 9 including means spacing apart the upstream retaining means and end piece and forming therebetween a recess at the upstream end of the chamber.
  • the spacing means comprises a peripheral boss on the upstream end piece projecting inward therefrom for abutment by the upstream retaining means.
  • the blood filter of claim 9 including baffle means opposite the inlet port for diffusing the blood laterally over the entire area of the blood filter material.
  • the blood filter of claim 13 wherein thebaffle means comprises an imperforate central portion of the upstream retaining means.

Abstract

Stored human blood is treated preliminary to blood transfusions by passing it through a mat of glass wool or other fibrous material which removes from the blood the storage-generated platelet leukocyte aggregates present therein. It is filtered during open heart surgery by passing it through the same material for removal of aggregates and leukocytes and separation of entrained air.

Description

United States Patent [72| Inventor Roy Lever Swank 4400 SW, Scholls ferry Road, Portland, Oreg. 97225 211 Appl. No. 882,663
[22] Filed Dec. 5, 1969 [45] Patented July 20, 1971 Continuation-impart of application Ser. No. 826,480, May 21, 1969, now abandoned.
[54] BLOOD TREATING AND FILTERING APPARATUS 14 Claims, 8 Drawing Figs.
[52] U.S. Cl 210/436, 210/445, 210/446, 210/491 [51] lnLCl ..B0ld 29/08 [50] Field ofSearch 210/65,
[ 56] References Cited UNITED STATES PATENTS 164,257 6/1875 Brach 210/445 X 638,742 12/1899 Murphy 210/436 X 865,691 9/ 1 907 Fox H .1 210/445 2,238,426 6/1942 Stack.... 210/489 2,776,055 1/1957 Adler 210/445 X 3,003,643 10/1961 Thomas... 210/491 X 3,448,041 6/1969 Swank 210/446 X 3,462,361 8/ 1969 Greenwalt et al .f. 210/446 X Primary Exam iner-J L. Decesare AttorneyEugene D. Farley- ABSTRACT: Stored human blood is treated preliminary to blood transfusions by passing it through a mat of glass wool or other fibrous material which removes from the blood the storage-generated platelet leukocyte aggregates present therein. It is filtered during open heart surgery by passing it through the same material for removal of aggregates and leukocytes and separation of entrained air.
PATENTEB JULZO 1911 SHEU 1 BF 2 QE EL Z 3352c o o. 3 on ow on 3 o ow on Ov On On INVENTOR. ROY LAVER SWANK ATTY.
PATENTED JUL20 l9?! sum 2 [1F 2 INVENTOR. BOY LAVEH SWANK BY by:
ATTY
BLOOD TREATING AND FILTERING APPARATUS This application is a continuation-in-part of the patent application of Roy L. Swank, Ser. No. 826,480, filed May 21, 1969 for Blood Treating Method and Apparatus, now abandoned.
In blood transfusions and heart surgery it has become routine to employ blood bank blood. This is prepared by withdrawing blood from donors, adding heparin or other preservative, and then storing the blood under carefully controlled conditions until its use is required.
Whether it is used directly in transfusions or in heart surgery, there sometimes have been observed in the patient an ensuing cessation of circulation and other reactions not attributable to mismatching of blood types. Although the cause of this regrettable result has been unknown, it has been recognized as a function of blood storage duration. Accordingly, it has been commonpractice to discard blood bank blood after it has been stored for a predetermined time.
Another difficult problem exists when handling blood dur' ing heart surgery, kidney dialysis, etc. In these procedures not only is the blood altered to produce harmful constituents, but it becomes contaminated with extraneous material such as epithelium, pieces of muscle, fat emboli, fragments of suture material and entrained air. This foreign material must be removed in order successfully to consummate the surgical procedure.
It is the general object of this invention to provide method and apparatus for treating blood to be used in transfusions and heart surgery which will overcome the foregoing problem, reducing the likelihood of transfusion reactions due to circulatory failure and related conditions, and enabling the use of blood bank blood even though it has been stored for long periods of time.
Another object is the provision of a continuous, high capacity, blood filter which contemporaneously filters and deaerates the blood.
In the drawings:
FIG. 1 is a longitudinal sectional view of the herein described blood treating apparatus, as used in transfusing blood;
FIGS. 2 and 3 are plan views of support elements employed in the apparatus of FIG. 1;
FIGS. 4 and S are graphs illustrating the effect of fiber diameter and filter density on the performance of filters contained in the apparatus; and
FIGS.'6, 7 and 8 are sectional, exploded and schematic views illustrating respectively, the construction and application of a modified form of the apparatus, as used in heart surgery.
It has been discovered that when blood bank blood is stored, its leukocyte and platelet components are altered, developing characteristics which are responsible for the transfusion complications described above. The alteration is evidenced in two ways. First, some of the platelets become adhesive. Second, some of the platelets form aggregates with some of the leukocytesfl'he aggregates primarily are responsible for the adverse results occurring when old blood is used in blood transfusions.
In view of the correlation between the altered component content of the stored blood and the occurrence of transfusion complications when such blood is applied in medical practice, the importance of removing these altered components prior to transfusion and during heart surgery becomes strikingly apparent.
The present invention provides an efficient method and apparatus for accomplishing the removal of such components.
FIGS. l3 illustrate apparatus for use particularly in transfusions. The apparatus comprises a tube 10 which may be made of rigid material such as glass, but which preferably is made of a nonpyrogenic, sterilizable, resilient material such as polyethylene plastic. Such material makes of the tube a hand pump so that the flow of blood through the apparatus maybe increased by slowly compressing the tube sidewalls in the manner shown in dotted outline in FIG. I.
Since the blood preferably passes through the apparatus by gravity flow, tube 10 normally is arranged vertically and has at its upper end an inlet port and at its lower end an outlet-port.
To facilitate application of the apparatus in blood transfusions, the inlet port of the tube preferably is fitted with a hollow, penetrating spur 12 adapted to pierce the cap 14 of a bottle 16 of blood bank blood.
Spur 12 preferably extends inwardly within tube 10 and accordingly acts as a metering device by which drop flow of blood may be monitored. The open lower end of tube 10 is fitted with a cap 18 having an integral valve chamber 20 and a stub exhaust conduit 22. A ball valve assembly 24 is seated within the valve chamber better to control the flow of blood during pumping of tube 10. The ball. valve assembly may be omitted, however, where the head of blood in container 16 is sufficient to prevent reverse flow.
A rubber tube or other conduit 26 is attached to stub conduit 22. It conveys the blood to the patient, usually through an interposed flow valve.
Tube 10 thus provides a housing for filter elements which selectively remove the undesirable altered components of the stored blood. To this end there are welded or otherwise secured to the inner sidewalls of the lower portion of the tube, below the pumping area, an upper support 28, an intermediate support 30, and a lower support 32. Upper support 28 is illustrated in detail in FIG. 2 while lower supports 30, 32 which may be substantially identical, are illustrated in FIG. 3. All three supports may be made from substantially rigid plastic.
Support 28 mounts a blood clot filter screen 34 of stainless steel or other suitable material. It has a screen size dimensioned to screen out any clots which may be present in the blood.
Support 28 also guides the blood to the central area of the tube To this end it comprises a ring 36 which is glued or otherwise affixed to the inner walls of tube 10 and an inwardly pro jecting, annular flange 38. The latter has inwardly extending projections 40, particularly evident in FIG. 2.
Supports 30, 32, on the other hand, serve the function of supporting the filter material. Each comprises a ring 42 mounting a characteristic pattern of crosspieces 44. Ring 42, like ring 36, is glued or otherwise fastened to the inner wall of the tube.
The three support rings thus provide three chambers 46, 48, 50 of progressively smaller volume. These chambers contain the filter material determining the desired performance of the filter.
Chambers 46, 48 contain the filter material 52 responsible for removing the blood aggregates and the altered leukocytes and platelets. For use in this application, the filter material must adhere these storage-altered components selectively; must permit free passage of the other blood components; must have a large area of absorbing surface; must not be nonpyrogenic; must not pack; must not collapse nor plug; and must not be affected adversely by repeated subjection to heat and chemical sterilization.
To meet the foregoing requirements, the filter material is used as filaments or fibers which may be formed into a resilient mat compressible as required to produce passageways or channels of optimum size. The diameter or cross-sectional area of the individual particles of the material is of primary importance in determining its suitability.
In general, as will be demonstrated hereinafter, the material should comprise fibers or filaments having lengths of not less than microns and diameters of less than 60 microns, preferably less than 30 microns. Such fibers are sufficiently large so that they will not pass through the filter and into the bloodstream of the patient. They are sufficiently small in diameter so that the storagealtered aggregates can completely surround them with overlapping portions which stick to each other, anchoring the aggregates to the fibers.
Material suitable for the present invention purpose thus are fibrous or filamentous polyester resins (Dacron and kodel), filter polyamide resin (Nylon), filamentous polyacrylic resin (Orlon), glass wool, steel wool, cotton, and cellulose (paper). However, the fibrous or filamentous materials meeting the above noted requirements may also be used.
In achieving the purposes of the invention, it further is desirable that the upstream portion of the filter material should be rather loosely packed to allow penetration of the large aggregates and their distribution through the entire .filter, thus increasing its capacity. Downstream, there should be provided a quantity of the filter material which is relatively closely packed. This provides the large surface area necessary to selectively absorb the storage altered components of smaller size.
Chamber 46, and to a certain extent the interior of domeshaped clot filter 34, receive the more loosely packed filter material. The central opening and inwardly directed projections 40 of support 28 allow the filter material to fluff up above the support, without freely escaping from the chamber below.
Chamber 48 receives the more tightly packed filter material. In general, it may be packed to advantage from two to four times more densely than the filter material contained in chamber 46, i.e. to a density of from 0.1 to 0.4 grams per cubic centimeter.
Chamber 50 receives a sponge filter 54 having for its function preventing fragments of the filer material contained in the superimposed chambers from reaching conduit 26, and hence the blood stream of the patient. The sponge filter preferably has a pore size of 60 to 100 pores per square inch. It preferably comprises porous polyurethane or other porous plastic. In the alternative, it may comprise a stainless steel screen or sponge.
The importance of filter element diameter and degree of compression in chamber 48 has been determined by tests, the results of which are shown in FIGS. 4 and 5.
To determine the effect of filter material diameter, the apparatus of FIG. 1 was filled with filter materials of varying identity and cross-sectional dimensions. Blood bank blood outdated by several weeks was gravitated through the apparatus at room temperature.
The treated blood then was tested for the presence of residual storage-altered components, i.e. adhesive platelets, and leukocytes and aggregates of the same by passing it through the pressure test apparatus described in the patent of Roy L. Swank, U.S. Pat. No. A 3,266,299, and measuring the developed filtration pressure. The results follow in Table l (defiberized paper) It will be observed from the table and graph that the efficiency of the treatment is afiected markedly by the diameter of the packing fibers. To be effective, the fibers should have diameters of less than 60 microns, preferably less than 30 microns. As the diameter decreases, the efficiency of the altered blood component removal increases dramatically.
To test the effect of filter material compression in chamber 48, samples of clot-free blood were allowed to flow gravitationally through the filter packed with packings of varying density. In each case the same amount of blood was employed and the time noted for passage through the filter. The results are given in FIG. 5.
It will be noted that a marked point of inflection occurs at a density of about 0.2 grams per cc. In general, best results are obtained where the density of the filtering material lies within the range of from 0.1 to 0.4 grams per cc. At lower densities, efficient filtration is not obtained. At higher densities, the filtration rate is too slow to be practical.
In the use of the filter stored blood contained in the container 16 passes through hollow spur 12 which meters it dropwise into resiliently collapsible tube 10. There it passes first through clot filter 34, which screens out the clots, and onto flange 38 of support 28, which directs it centrally of the tube.
Within clot filter 34, and to a greater extent within camber 46 through which it next flows, the blood contacts loosely packed filter material 52 contained in camber 46. This removes the larger aggregates.
Next, it flows through more tightly packed filter material 52 contained in chamber 48 which selectively removes the storage-altered leukocytes and aggregates of smaller size.
Next it passes through sponge or screen filter 54 which prevents particles of the filter material from leaving the apparatus and entering the bloodstream of the patient.
While this is occurring, the upper resiliently deformable portion of the tube 10 may be slowly compressed and allowed to re-expand. This pumps the blood through the filter and makes possible rapid transfusion in emergency situations.
FIGS. 6, 7 and 8 illustrate apparatus useful for filtering blood during open heart surgery, kidney dialysis procedures, etc. The general arrangement of the various units employed in the system is illustrated particularly in FIG. 8.
A conduit may be tied to the superior or inferior vena cava 112 using known techniques. A branch conduit 114 having a suction tip 115 made of stainless steel or other inert material is placed in the chest cavity for removal of accumulated blood.
Conduit 110 and 114 merge to form main conduit 116 which transfers the blood to a reservoir 1 18 of suitable capacity.
The blood then passes through a first pump 120, an oxygenator 122 and a second pump 124. The latter discharges it into the herein described blood treating and filtering apparatus 126. It should be noted, however, that this apparatus may be located variously in the system to meet the needs of various situations. Typical alternate locations are illustrated in dotted outline.
The oxygenated, treated, and filtered blood then continues through conduit 116, the discharge end of which is tied into the femoral or other artery 128.
The construction and manner of assembly of blood treating and filtering unit 126 is shown in detail in FIGS. 6 and 7.
The unit comprises an upstream end piece 130, a downstream end piece 132 and a tubular body 134. End pieces 130, 132 may be made from stainless steel or plastic, while body 134 may be made from transparent plastic or glass.
The upstream end piece is provided with a central inlet port 136 with outwardly projecting nipple 138 for attachment of one segment of conduit 116. The downstream end piece 132 is provided with a discharge port 140 communicating with a nipple 142 designed to receive another length of conduit 1 16.
These three elements of the unit, i.e. upstream and downstream end pieces 130, 132, and body 134 provide a central chamber 144 arranged for horizontal flow of the blood. The chamber is sealed by providing in the inner face of the end piece 130 an annular groove 146 seen clearly in FIG. 7. A similar groove, not visible in the same figure, is present in end piece 132. Seal rings I48, 150 are seated in the grooves.
The entire assembly then is clamped together with the parts in sealed relationship by suitable means such as bolts 152 penetrating one of the end pieces and threaded into the other.
Housed within chamber 144 in laterally spaced relation to the two end pieces is a blood treating and filtering assembly comprising a mat 154 of filter material, a perforated, upstream filter-material retainer 156, a screen 158, and a downstream filter-material retainer 160.
Retainers 156, 160 serve to locate filter element 154 centrally in the path of flow of the blood. They may be fabricated from suitable durable inert material such as stainless steel or plastic.
Screen 158 serves to screen out pieces of filter material 154 which otherwise might be entrained in the blood. It may be made of fine mesh stainless steel, Nylon or other suitable material.
Baffle means prevent channeling of the blood through the central-part of filter 154 and insure that the blood diffuses through the entire filter area, thus insuring efficient filtration. in the illustrated form of the invention, the baffle means comprises a central, unperforated section 156a of perforated retainer 156. This is located directly opposite inlet port 136.
Further to improve the efficiency of the filter, and to enable it to removeentrained air, the subassembly including elements 154, 156, 158 and 160 are maintained spaced apart from end pieces 130, 132. This provides an infeed recess 144a and an outfeed recess 1 14b.
Although various structural arrangements may be provided for accomplishing this purpose, a preferred arrangement comprises forming infeed end plate 130 with a peripheral boss 162 and outfeed end plate 132 with a similar peripheral boss 164. These serve as spacers by providing shoulders against which the margins of retaining plates 156, 160 bear in the final assembly of the apparatus.
Recess 144a, cooperating with baffle area 156a of retaining plate 156, serves the valuable function of causing distribution of the blood over the entire filter area.
Recess l44b at the downstream end of the unit serves the valuable function of providing an air trap which permits removal of entrained air from the blood. Such air, when it reaches the downstream end of the unit, will bubble upwardly to the top of recess 14417. There it passes through a port 166 located at the to of end piece 132. A nipple 168 is received in the port and mounts a valve 170 which may be used to exhaust the air as desirable or necessary.
Thus in the application of the form of the invention illustrated in H68. 6, 7 and 8, blood entering through inlet port 136 spreads out over the area of the filter in recess 144a, and passes through filter 154, into recess 1441) where the entrained air bubbles upwardly and escapes via port 166.
The filter element removes the altered leukocytes and platelets, the leukocyte-platelet aggregates, the fat emboli, the epithelium, the pieces of muscle and suture material, and other debris from the blood. This all is accomplished efficiently, continuously and at a high rate sufiicient to accommodate the needs of open heart surgery techniques.
Having thus described my invention in preferred embodiments, 1 claim as new and desire to protect by Letters Patent:
1. Apparatus for treat, preliminary to medical application, human blood containing platelet-leukocyte aggregates, the apparatus comprising:
a. a vessel having an inlet port near one end and an outlet port near the other end,
b. within the vessel between the inlet and outlet ports, a
filter assembly comprising 1. a blood clot filter member,
2. downstream from the blood clot filter member a first meat of finely subdivided blood-contact material comprising a solid fibrous material the fibers of which are nondegrading to the blood and characterized by the ability selectively to adhere the aggregates,
3. downstream from the first mat a second mat of finely subdivided blood-contact material comprising a solid fibrous material the fibers of which are nondegrading to the blood and characterized by the ability selectively to adhere the aggregates, the second mat having a density greater than the first mat for selectively removing aggregates of smaller size, 4. ownstream from the second mat fiber filter member for filtering from the blood fragments of mat fiber filter material,
c. means for introducing stored blood into a inlet port and for passing it through the filter assembly,
d. and means for withdrawing the treated blood from the outlet port.
2. The apparatus of claim 1 wherein the vessel has resiliently deformable sidewalls on the upstream side of the filter assembly adapted to be compressed and re-expanded for pumping blood through the apparatus.
3. The apparatus of claim 1 including a. a first perforate support member between the blood clot filter member and the first mat, supporting the blood clot filter member and compressing the first mat, and
b. a second perforate support member between the first and second mats supporting the first mat and compressing the second mat.
4. The apparatus of claim 3 wherein the blood clot filter member comprises a dome-shaped screen support at its open end on the first support member, the latter having a central opening through which the first mat projects into the spacing defined by the screen.
5. The apparatus of claim 4 including inwardly extending projections on the first support member engaging the first mat to prevent free escape of the latter into the space defined by the screen.
6. The apparatus of claim 1 including valve means adjacent the outlet port operable to prevent lback flow of blood from the outlet port into the vessel.
7. The apparatus of claim 1 wherein the second mat of fibrous material has a density of about 0.1 to 0.4 grams per cc.
8. The apparatus of claim 1 wherein the mat fiber has a diameter not substantially great than about 30 microns, the density of the second mat is about 0 .2 grams per cc. and the density of the first mat is about %--%the density of the second mat.
9. A high volume, continuous blood filter comprising:
a. upstream and downstream end pieces,
b. a tubular body secured between the end pieces to form a chamber,
c. an inlet port at the center of the upstream end piece,
d. an outlet port below the top of the downstream end piece,
e. the inlet and outlet ports thereby enabling substantially horizontal blood flow through the chamber,
f. a quantity of blood-filter material between the end pieces,
g. upstream perforated, filter-material-retaining means locating the filter material in the path of the blood flow,
h. means spacing apart the downstream retaining means and end piece and forming therebetween a recess at the downstream end of the chamber for separating and collecting air entrained in the blood, and
i. air-exhaust port means communicating with the top of the recess for exhausting collected air therefrom.
10. The blood filter of claim 9 wherein spacing means comprises a peripheral boss on the downstream end piece projecting inward therefrom for abutment by the downstream retaining means.
11. The blood filter of claim 9 including means spacing apart the upstream retaining means and end piece and forming therebetween a recess at the upstream end of the chamber.
12. The blood filter of claim 11 wherein the spacing means comprises a peripheral boss on the upstream end piece projecting inward therefrom for abutment by the upstream retaining means.
13. The blood filter of claim 9 including baffle means opposite the inlet port for diffusing the blood laterally over the entire area of the blood filter material.
14. The blood filter of claim 13 wherein thebaffle means comprises an imperforate central portion of the upstream retaining means.
UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No- 3,593,854 Dated July 201 l97l Roy Lever Swank Inventor(s) It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 5, line 57, "treat" should read treating Column 6, line 3, after "mat", second occurrence, insert a mat line 49, after "u stream" insert and downstream line 57, after wherein" insert the Signed and sealed this 10th day of October 1972.
(SEAL) Attest:
EDWARD M.FLETCHER,JR. ROBERT GO'ITSCHALK Attesting Officer Commissioner of Patents USCOMM-DC 80376-0 69 FORM PO-1050 (10-69? a u.s eovsmmim mmnmo orncs: Inn o-sssa. u.

Claims (16)

  1. 2. downstream from the blood clot filter member a first meat of finely subdivided blood-contact material comprising a solid fibrous material the fibers of which are nondegrading to the blood and characterized by the ability selectively to adhere the aggregates,
  2. 2. The apparatus of claim 1 wherein the vessel has resiliently deformable sidewalls on the upstream side of the filter assembly adapted to be compressed and re-expanded for pumping blood through the apparatus.
  3. 3. The apparatus of claim 1 including a. a first perforate support member between the blood clot filter member and the first mat, supporting the blood clot filter member and compressing the first mat, and b. a second perforate support member between the first and second mats supporting the first mat and compressing the second mat.
  4. 3. downstream from the first mat a second mat of finely subdivided blood-contact material comprising a solid fibrous material the fibers of which are nondegrading to the blood and characterized by the ability selectively to adhere the aggregates, the second mat having a density greater than the first mat for selectively removing aggregates of smaller size,
  5. 4. downstream from the second mat fiber filter member for filtering from the blood fragments of mat fiber filter material, c. means for introducing stored blood into a inlet port and for passing it through the filter assembly, d. and means for withdrawing the treated blood from the outlet port.
  6. 4. The apparatus of claim 3 wherein the blood clot filter member comprises a dome-shaped screen support at its open end on the first support member, the latter having a central opening through which the first mat projects into the spacing defined by the screen.
  7. 5. The apparatus of claim 4 including inwardly extending projections on the first support member engaging the first mat to prevent free escape of the latter into the space defined by the screen.
  8. 6. The apparatus of claim 1 including valve means adjacent the outlet port operable to prevent back flow of blood from the outlet port into the vessel.
  9. 7. The apparatus of claim 1 wherein the second mat of fibrous material has a density of about 0.1 to 0.4 grams per cc.
  10. 8. The apparatus of claim 1 wherein the mat fiber has a diameter not substantially great than about 30 microns, the density of the second mat is about 0.2 grams per cc. and the density of the first mat is about 1/4 - 1/2 the density of the second mat.
  11. 9. A high volume, continuous blood filter comprising: a. upstream and downstream end pieces, b. a tubular body secured between the end pieces to form a chamber, c. an inlet port at the center of the upstream end piece, d. an outlet port below the top of the downstream end piece, e. the inlet and outlet ports thereby enabling substantially horizontal blood flow through the chamber, f. a quantity of blood-filter material between thE end pieces, g. upstream perforated, filter-material-retaining means locating the filter material in the path of the blood flow, h. means spacing apart the downstream retaining means and end piece and forming therebetween a recess at the downstream end of the chamber for separating and collecting air entrained in the blood, and i. air-exhaust port means communicating with the top of the recess for exhausting collected air therefrom.
  12. 10. The blood filter of claim 9 wherein spacing means comprises a peripheral boss on the downstream end piece projecting inward therefrom for abutment by the downstream retaining means.
  13. 11. The blood filter of claim 9 including means spacing apart the upstream retaining means and end piece and forming therebetween a recess at the upstream end of the chamber.
  14. 12. The blood filter of claim 11 wherein the spacing means comprises a peripheral boss on the upstream end piece projecting inward therefrom for abutment by the upstream retaining means.
  15. 13. The blood filter of claim 9 including baffle means opposite the inlet port for diffusing the blood laterally over the entire area of the blood filter material.
  16. 14. The blood filter of claim 13 wherein the baffle means comprises an imperforate central portion of the upstream retaining means.
US882663A 1969-12-05 1969-12-05 Blood treating and filtering apparatus Expired - Lifetime US3593854A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88266369A 1969-12-05 1969-12-05

Publications (1)

Publication Number Publication Date
US3593854A true US3593854A (en) 1971-07-20

Family

ID=34116959

Family Applications (1)

Application Number Title Priority Date Filing Date
US882663A Expired - Lifetime US3593854A (en) 1969-12-05 1969-12-05 Blood treating and filtering apparatus

Country Status (4)

Country Link
US (1) US3593854A (en)
DE (1) DE1928052A1 (en)
FR (1) FR2048130A5 (en)
GB (1) GB1242493A (en)

Cited By (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3770129A (en) * 1972-05-15 1973-11-06 Harvey W Res Corp Manually flexible blood filter
FR2189081A1 (en) * 1972-06-16 1974-01-25 Pall Corp
USB302271I5 (en) * 1972-10-30 1975-01-28
US3873682A (en) * 1971-02-23 1975-03-25 Mochida Pharm Co Ltd Filter for urine samples to be used in pregnancy tests and method of using same
JPS519594U (en) * 1974-06-08 1976-01-23
US3935111A (en) * 1973-04-06 1976-01-27 Bentley Laboratories, Inc. Device for removing blood microemboli
US3963614A (en) * 1970-11-09 1976-06-15 Hitachi, Ltd. Apparatus for removing unnecessary components from samples
US3972818A (en) * 1974-08-22 1976-08-03 General Atomic Company Blood filter using glassy carbon fibers
US3986506A (en) * 1974-09-03 1976-10-19 Baxter Travenol Laboratories, Inc. Apparatus for separation of cryoprecipitate from blood plasma and method
US4053420A (en) * 1975-04-14 1977-10-11 Dr. Eduard Fresenius Chemisch-Pharmazeutische Industrie Kg. Blood filter
US4056476A (en) * 1975-02-27 1977-11-01 Johnson & Johnson Blood filter media
US4073732A (en) * 1974-04-19 1978-02-14 Johnson & Johnson Media for filtering blood
US4073723A (en) * 1976-11-15 1978-02-14 Swank Roy L Anti-coagulating and filtering blood
US4096070A (en) * 1977-01-03 1978-06-20 Johnson & Johnson Blood filter
US4115277A (en) * 1977-06-17 1978-09-19 Pioneer Filters, Inc. Blood filtering apparatus of graduated fiber density
US4116845A (en) * 1977-06-17 1978-09-26 Pioneer Filters, Inc. High capacity blood transfusion micro filter
US4129131A (en) * 1976-10-26 1978-12-12 Henry Naftulin Method and apparatus for defibrination of blood
US4155854A (en) * 1975-04-14 1979-05-22 Dr. Eduard Fresenius Chemischpharmazeutische Industrie KG. Blood filter
US4157965A (en) * 1975-01-20 1979-06-12 Bentley Laboratories, Inc. Blood treating device
US4157967A (en) * 1976-03-25 1979-06-12 Baxter Travenol Laboratories, Inc. Blood filter
US4162220A (en) * 1977-01-03 1979-07-24 Johnson & Johnson Blood filter
US4170056A (en) * 1976-03-25 1979-10-09 Baxter Travenol Laboratories, Inc. Blood filter
US4190542A (en) * 1973-07-26 1980-02-26 Smith & Nephew Research Ltd. Disposable column
DE2846302A1 (en) * 1977-08-01 1980-05-08 Pioneer Filters Inc HIGH CAPACITY BLOOD TRANSFUSION MICROFILTER
JPS55129755A (en) * 1979-03-30 1980-10-07 Asahi Chem Ind Co Ltd Catch and pick-up filter of white corpuscle
US4253967A (en) * 1975-01-20 1981-03-03 Bentley Laboratories, Inc. Blood treating method
US4283289A (en) * 1979-08-22 1981-08-11 Baxter Travenol Laboratories, Inc. Blood filter for leukocytes
JPS5755152A (en) * 1980-09-18 1982-04-01 Toray Industries Therapeutic molded object provided with x-ray contrasting property
US4330410A (en) * 1978-03-06 1982-05-18 Asahi Kasei Kogyo Kabushiki Kaisha Separation of leukocytes from leukocyte-containing suspension by filtration
EP0155003A2 (en) * 1984-03-15 1985-09-18 ASAHI MEDICAL Co., Ltd. Filtering unit for removing leukocytes
US4668394A (en) * 1983-01-10 1987-05-26 Mcneilab, Inc. Filtration media and supporting frame
US4743371A (en) * 1983-04-08 1988-05-10 Shiley, Inc. Blood filter
US4880548A (en) * 1988-02-17 1989-11-14 Pall Corporation Device and method for separating leucocytes from platelet concentrate
US4923620A (en) * 1987-10-20 1990-05-08 Pall Corporation Device for depletion of the leukocyte content of blood and blood components
US4925572A (en) * 1987-10-20 1990-05-15 Pall Corporation Device and method for depletion of the leukocyte content of blood and blood components
US4954251A (en) * 1989-01-31 1990-09-04 Miles Inc. Concentric microaggregate blood filter
US5045096A (en) * 1988-09-21 1991-09-03 Quang Minh B Devices for de-aerating liquids flowing in medical liquid systems
US5139685A (en) * 1991-03-26 1992-08-18 Gds Technology, Inc. Blood separation filter assembly and method
US5229012A (en) * 1989-05-09 1993-07-20 Pall Corporation Method for depletion of the leucocyte content of blood and blood components
US5258126A (en) * 1989-09-12 1993-11-02 Pall Corporation Method for obtaining platelets
US5258127A (en) * 1990-07-27 1993-11-02 Pall Corporation Leucocyte depleting filter device and method of use
US5302299A (en) * 1990-05-24 1994-04-12 Pall Corporation Biological semi-fluid processing assembly
US5344561A (en) * 1989-05-09 1994-09-06 Pall Corporation Device for depletion of the leucocyte content of blood and blood components
US5360545A (en) * 1989-09-12 1994-11-01 Pall Corporation Filter for obtaining platelets
US5362406A (en) * 1990-07-27 1994-11-08 Pall Corporation Leucocyte depleting filter device and method of use
US5472605A (en) * 1994-03-10 1995-12-05 Hemasure, Inc. Filtration device useable for removal of leukocytes and other blood components
US5575914A (en) * 1994-12-23 1996-11-19 Vance Products Incorporated Sperm filter trap having compressed glass wool filter material
US5630946A (en) * 1995-02-15 1997-05-20 Pall Corporation Method for processing a biological fluid including leukocyte removal in an extracorporeal circuit
US5837140A (en) * 1995-05-29 1998-11-17 Dideco S.P.A Blood filter and extracorporeal circuit
US5863436A (en) * 1990-05-24 1999-01-26 Pall Corporation Venting system
US6010633A (en) * 1997-03-06 2000-01-04 Hemasure Inc. Method of preventing air from becoming entrapped within a filtration device
US6048464A (en) * 1995-12-26 2000-04-11 Asahi Medical Co., Ltd. Filter medium for leukocyte removal, method of making, and method of using thereof
US6086770A (en) * 1990-05-24 2000-07-11 Pall Corporation Venting system
US6221264B1 (en) * 1998-05-19 2001-04-24 Terumo Kabushiki Kaisha White blood cell-removing device, white blood cell-removing apparatus and white blood cell-removing method
US6251292B1 (en) 1994-03-10 2001-06-26 Hemasure, Inc. Method of preventing air from becoming entrapped within a filtration device
US20020120224A1 (en) * 2001-01-31 2002-08-29 Majid Zia Multi-purpose tubing apparatus
US20020143298A1 (en) * 2001-03-30 2002-10-03 Becton, Dickinson And Company Blunt cannula and filter assembly and method of use with point-of-care testing cartridge
US6497685B1 (en) 2000-03-24 2002-12-24 Baxter International Inc. Integral intravenous chamber and filter
US20030085167A1 (en) * 2001-11-07 2003-05-08 Fox John Edward Dual density filter cartridge
US6905479B1 (en) * 1999-07-20 2005-06-14 Deka Products Limited Partnership Pumping cartridge having an integrated filter and method for filtering a fluid with the cartridge
US20050256460A1 (en) * 2004-05-12 2005-11-17 Guy Rome Valved connector
US20050256457A1 (en) * 2004-05-12 2005-11-17 Guy Rome Hemostasis valve for a catheter
US20060127875A1 (en) * 2001-05-07 2006-06-15 Sivaprasad Sukavaneshvar Device for separation of platelets from whole blood
US7153425B2 (en) * 1999-09-17 2006-12-26 Entegris, Inc. Process and filter for filtering a slurry
US20070037132A1 (en) * 2001-05-07 2007-02-15 Sivaprasad Sukavaneshvar Separation of platelets from fluid suspensions
US20070108117A1 (en) * 2005-08-31 2007-05-17 Wim Callaert Fluid filter
US7247245B1 (en) * 1999-12-02 2007-07-24 Entegris, Inc. Filtration cartridge and process for filtering a slurry
US20080147012A1 (en) * 2004-05-12 2008-06-19 C.R.Bard, Inc. Catheter with Removable Extension
US20080260593A1 (en) * 2000-03-22 2008-10-23 Dewalch Norman Binz Method and apparatus for processing substances in a single container
US20100296953A1 (en) * 1999-07-20 2010-11-25 Deka Products Limited Partnership Pump chamber configured to contain a residual fluid volume for inhibiting the pumping of a gas
US20120219633A1 (en) * 2011-02-28 2012-08-30 Pall Corporation Removal of immunoglobulins and leukocytes from biological fluids
US8337700B1 (en) * 2005-02-24 2012-12-25 Hemerus Medical, Llc High capacity biological fluid filtration apparatus
US8398672B2 (en) 2003-11-12 2013-03-19 Nitinol Devices And Components, Inc. Method for anchoring a medical device
US9572918B2 (en) 2013-06-21 2017-02-21 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
US9610546B2 (en) 2014-03-12 2017-04-04 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US9649211B2 (en) 2009-11-04 2017-05-16 Confluent Medical Technologies, Inc. Alternating circumferential bridge stent design and methods for use thereof
US9744617B2 (en) 2014-01-31 2017-08-29 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
US9833748B2 (en) 2010-08-25 2017-12-05 Lockheed Martin Corporation Perforated graphene deionization or desalination
US9844757B2 (en) 2014-03-12 2017-12-19 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US9870895B2 (en) 2014-01-31 2018-01-16 Lockheed Martin Corporation Methods for perforating two-dimensional materials using a broad ion field
US10005038B2 (en) 2014-09-02 2018-06-26 Lockheed Martin Corporation Hemodialysis and hemofiltration membranes based upon a two-dimensional membrane material and methods employing same
US10017852B2 (en) 2016-04-14 2018-07-10 Lockheed Martin Corporation Method for treating graphene sheets for large-scale transfer using free-float method
US10092427B2 (en) 2009-11-04 2018-10-09 Confluent Medical Technologies, Inc. Alternating circumferential bridge stent design and methods for use thereof
US10118130B2 (en) 2016-04-14 2018-11-06 Lockheed Martin Corporation Two-dimensional membrane structures having flow passages
US10201784B2 (en) 2013-03-12 2019-02-12 Lockheed Martin Corporation Method for forming perforated graphene with uniform aperture size
US10203295B2 (en) 2016-04-14 2019-02-12 Lockheed Martin Corporation Methods for in situ monitoring and control of defect formation or healing
US10213746B2 (en) 2016-04-14 2019-02-26 Lockheed Martin Corporation Selective interfacial mitigation of graphene defects
US10376845B2 (en) 2016-04-14 2019-08-13 Lockheed Martin Corporation Membranes with tunable selectivity
US10418143B2 (en) 2015-08-05 2019-09-17 Lockheed Martin Corporation Perforatable sheets of graphene-based material
US10500546B2 (en) 2014-01-31 2019-12-10 Lockheed Martin Corporation Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer
CN110799225A (en) * 2017-06-10 2020-02-14 费森尤斯医疗护理德国有限责任公司 Device for extracorporeal blood treatment and device for collecting blood clots and method for determining hemodynamic parameters during extracorporeal blood treatment
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
US10696554B2 (en) 2015-08-06 2020-06-30 Lockheed Martin Corporation Nanoparticle modification and perforation of graphene
US10980919B2 (en) 2016-04-14 2021-04-20 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials
WO2022066664A1 (en) * 2020-09-23 2022-03-31 Carefusion 303, Inc. Intravenous filter
US11612683B2 (en) 2018-07-24 2023-03-28 Healeon Llc Device and method for resizing adipose and other tissues for implantation

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3951147A (en) * 1975-04-07 1976-04-20 Metal Bellows Company Implantable infusate pump
DE2559332C3 (en) * 1975-12-31 1981-04-09 Berthold 5439 Elsoff Schilling membrane
GB2041233B (en) * 1979-02-14 1983-08-17 Fresenius Chem Pharm Ind Blood filter
GB2077137B (en) * 1980-03-12 1983-09-07 Asahi Chemical Ind Granulocyte-separating material and granulocyte separator
DK157218C (en) * 1981-07-06 1990-04-23 Per Stahl Skov PROCEDURE FOR DETERMINING OR DETERMINING HISTAMINE IN BODY LIQUIDS, SPECIFIC BLOOD OR BLOOD FRACTIONS, AND ANALYTICAL DEVICE FOR APPLICATION BY PURPOSE OF THE PROCEDURE
GB8606626D0 (en) * 1986-03-18 1986-04-23 Travenol Lab Ltd Parenteral administration apparatus
GB2242277B (en) * 1987-10-20 1992-07-01 Pall Corp Method for determining the wetting characteristics of a porous medium
IL88081A0 (en) * 1987-10-20 1989-06-30 Pall Corp Device and method for depletion of the leucocyte content of blood and blood components

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US164257A (en) * 1875-06-08 Improvement in water-filters
US638742A (en) * 1899-02-10 1899-12-12 New Era Carbonator Company Water-filter.
US865691A (en) * 1906-10-27 1907-09-10 John H Fox Pressure-filter.
US2288426A (en) * 1939-10-30 1942-06-30 Nat Automotive Fibres Inc Filter material
US2776055A (en) * 1954-08-13 1957-01-01 Medical Plastics Inc Blood filter with clot remover
US3003643A (en) * 1957-10-28 1961-10-10 Johnson & Johnson Filter media
US3448041A (en) * 1965-06-14 1969-06-03 Roy L Swank Method and apparatus for treating blood preliminary to its use in transfusions
US3462361A (en) * 1965-05-14 1969-08-19 Milwaukee Blood Center Inc Method and apparatus for treating blood

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US164257A (en) * 1875-06-08 Improvement in water-filters
US638742A (en) * 1899-02-10 1899-12-12 New Era Carbonator Company Water-filter.
US865691A (en) * 1906-10-27 1907-09-10 John H Fox Pressure-filter.
US2288426A (en) * 1939-10-30 1942-06-30 Nat Automotive Fibres Inc Filter material
US2776055A (en) * 1954-08-13 1957-01-01 Medical Plastics Inc Blood filter with clot remover
US3003643A (en) * 1957-10-28 1961-10-10 Johnson & Johnson Filter media
US3462361A (en) * 1965-05-14 1969-08-19 Milwaukee Blood Center Inc Method and apparatus for treating blood
US3448041A (en) * 1965-06-14 1969-06-03 Roy L Swank Method and apparatus for treating blood preliminary to its use in transfusions

Cited By (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963614A (en) * 1970-11-09 1976-06-15 Hitachi, Ltd. Apparatus for removing unnecessary components from samples
US3873682A (en) * 1971-02-23 1975-03-25 Mochida Pharm Co Ltd Filter for urine samples to be used in pregnancy tests and method of using same
US3770129A (en) * 1972-05-15 1973-11-06 Harvey W Res Corp Manually flexible blood filter
FR2189081A1 (en) * 1972-06-16 1974-01-25 Pall Corp
USB302271I5 (en) * 1972-10-30 1975-01-28
US3929130A (en) * 1972-10-30 1975-12-30 Thomas S Hargest Method for lymphocyte depletion
US3935111A (en) * 1973-04-06 1976-01-27 Bentley Laboratories, Inc. Device for removing blood microemboli
US4190542A (en) * 1973-07-26 1980-02-26 Smith & Nephew Research Ltd. Disposable column
US4073732A (en) * 1974-04-19 1978-02-14 Johnson & Johnson Media for filtering blood
JPS5740996Y2 (en) * 1974-06-08 1982-09-08
JPS519594U (en) * 1974-06-08 1976-01-23
US3972818A (en) * 1974-08-22 1976-08-03 General Atomic Company Blood filter using glassy carbon fibers
US3986506A (en) * 1974-09-03 1976-10-19 Baxter Travenol Laboratories, Inc. Apparatus for separation of cryoprecipitate from blood plasma and method
US4253967A (en) * 1975-01-20 1981-03-03 Bentley Laboratories, Inc. Blood treating method
US4157965A (en) * 1975-01-20 1979-06-12 Bentley Laboratories, Inc. Blood treating device
US4056476A (en) * 1975-02-27 1977-11-01 Johnson & Johnson Blood filter media
US4155854A (en) * 1975-04-14 1979-05-22 Dr. Eduard Fresenius Chemischpharmazeutische Industrie KG. Blood filter
US4053420A (en) * 1975-04-14 1977-10-11 Dr. Eduard Fresenius Chemisch-Pharmazeutische Industrie Kg. Blood filter
US4170056A (en) * 1976-03-25 1979-10-09 Baxter Travenol Laboratories, Inc. Blood filter
US4157967A (en) * 1976-03-25 1979-06-12 Baxter Travenol Laboratories, Inc. Blood filter
US4129131A (en) * 1976-10-26 1978-12-12 Henry Naftulin Method and apparatus for defibrination of blood
US4073723A (en) * 1976-11-15 1978-02-14 Swank Roy L Anti-coagulating and filtering blood
US4162220A (en) * 1977-01-03 1979-07-24 Johnson & Johnson Blood filter
US4096070A (en) * 1977-01-03 1978-06-20 Johnson & Johnson Blood filter
US4115277A (en) * 1977-06-17 1978-09-19 Pioneer Filters, Inc. Blood filtering apparatus of graduated fiber density
US4116845A (en) * 1977-06-17 1978-09-26 Pioneer Filters, Inc. High capacity blood transfusion micro filter
DE2846302A1 (en) * 1977-08-01 1980-05-08 Pioneer Filters Inc HIGH CAPACITY BLOOD TRANSFUSION MICROFILTER
US4330410A (en) * 1978-03-06 1982-05-18 Asahi Kasei Kogyo Kabushiki Kaisha Separation of leukocytes from leukocyte-containing suspension by filtration
JPS55129755A (en) * 1979-03-30 1980-10-07 Asahi Chem Ind Co Ltd Catch and pick-up filter of white corpuscle
JPS6324975B2 (en) * 1979-03-30 1988-05-23 Asahi Chemical Ind
US4283289A (en) * 1979-08-22 1981-08-11 Baxter Travenol Laboratories, Inc. Blood filter for leukocytes
JPS5755152A (en) * 1980-09-18 1982-04-01 Toray Industries Therapeutic molded object provided with x-ray contrasting property
JPH0140628B2 (en) * 1980-09-18 1989-08-30 Toray Industries
US4668394A (en) * 1983-01-10 1987-05-26 Mcneilab, Inc. Filtration media and supporting frame
US4743371A (en) * 1983-04-08 1988-05-10 Shiley, Inc. Blood filter
EP0155003A2 (en) * 1984-03-15 1985-09-18 ASAHI MEDICAL Co., Ltd. Filtering unit for removing leukocytes
EP0155003A3 (en) * 1984-03-15 1987-04-15 Asahi Medical Co., Ltd. Filtering unit for removing leukocytes
US4925572A (en) * 1987-10-20 1990-05-15 Pall Corporation Device and method for depletion of the leukocyte content of blood and blood components
US4923620A (en) * 1987-10-20 1990-05-08 Pall Corporation Device for depletion of the leukocyte content of blood and blood components
US4880548A (en) * 1988-02-17 1989-11-14 Pall Corporation Device and method for separating leucocytes from platelet concentrate
US5045096A (en) * 1988-09-21 1991-09-03 Quang Minh B Devices for de-aerating liquids flowing in medical liquid systems
US4954251A (en) * 1989-01-31 1990-09-04 Miles Inc. Concentric microaggregate blood filter
US5229012A (en) * 1989-05-09 1993-07-20 Pall Corporation Method for depletion of the leucocyte content of blood and blood components
US5501795A (en) * 1989-05-09 1996-03-26 Pall Corporation Device for depletion of the leucocyte content of blood and blood components
US5344561A (en) * 1989-05-09 1994-09-06 Pall Corporation Device for depletion of the leucocyte content of blood and blood components
US5258126A (en) * 1989-09-12 1993-11-02 Pall Corporation Method for obtaining platelets
US5360545A (en) * 1989-09-12 1994-11-01 Pall Corporation Filter for obtaining platelets
US6086770A (en) * 1990-05-24 2000-07-11 Pall Corporation Venting system
US5863436A (en) * 1990-05-24 1999-01-26 Pall Corporation Venting system
US5302299A (en) * 1990-05-24 1994-04-12 Pall Corporation Biological semi-fluid processing assembly
US5362406A (en) * 1990-07-27 1994-11-08 Pall Corporation Leucocyte depleting filter device and method of use
US5744047A (en) * 1990-07-27 1998-04-28 Pall Corporation Leucocyte depleting filter device and method of use
US5258127A (en) * 1990-07-27 1993-11-02 Pall Corporation Leucocyte depleting filter device and method of use
WO1993019831A1 (en) * 1991-03-26 1993-10-14 Gds Technology, Inc. Blood separation filter assembly and method
US5139685A (en) * 1991-03-26 1992-08-18 Gds Technology, Inc. Blood separation filter assembly and method
US5902490A (en) * 1994-03-10 1999-05-11 Hemasure, Inc. Filtration method and device useable for removal of leukocytes and other blood components
US6015500A (en) * 1994-03-10 2000-01-18 Hemasure Inc. Filtration device useable for removal of leukocytes and other blood components
US5472605A (en) * 1994-03-10 1995-12-05 Hemasure, Inc. Filtration device useable for removal of leukocytes and other blood components
US6251292B1 (en) 1994-03-10 2001-06-26 Hemasure, Inc. Method of preventing air from becoming entrapped within a filtration device
US5575914A (en) * 1994-12-23 1996-11-19 Vance Products Incorporated Sperm filter trap having compressed glass wool filter material
US5630946A (en) * 1995-02-15 1997-05-20 Pall Corporation Method for processing a biological fluid including leukocyte removal in an extracorporeal circuit
US5837140A (en) * 1995-05-29 1998-11-17 Dideco S.P.A Blood filter and extracorporeal circuit
US6048464A (en) * 1995-12-26 2000-04-11 Asahi Medical Co., Ltd. Filter medium for leukocyte removal, method of making, and method of using thereof
US6010633A (en) * 1997-03-06 2000-01-04 Hemasure Inc. Method of preventing air from becoming entrapped within a filtration device
US6221264B1 (en) * 1998-05-19 2001-04-24 Terumo Kabushiki Kaisha White blood cell-removing device, white blood cell-removing apparatus and white blood cell-removing method
US9593678B2 (en) 1999-07-20 2017-03-14 Deka Products Limited Partnership System, method, and apparatus for utilizing a pumping cassette
US9494150B2 (en) 1999-07-20 2016-11-15 Deka Products Limited Partnership Pump chamber configured to contain a residual fluid volume for inhibiting the pumping of a gas
US9494151B2 (en) 1999-07-20 2016-11-15 Deka Products Limited Partnership System, method, and apparatus for utilizing a pumping cassette
US9488167B2 (en) 1999-07-20 2016-11-08 Deka Products Limited Partnership System, method, and apparatus for utilizing a pumping cassette
US9039395B2 (en) 1999-07-20 2015-05-26 Deka Products Limited Partnership System, method, and apparatus for utilizing a pumping cassette
US8556225B2 (en) 1999-07-20 2013-10-15 Deka Products Limited Partnership Pump chamber configured to contain a residual fluid volume for inhibiting the pumping of a gas
US6905479B1 (en) * 1999-07-20 2005-06-14 Deka Products Limited Partnership Pumping cartridge having an integrated filter and method for filtering a fluid with the cartridge
US20100296953A1 (en) * 1999-07-20 2010-11-25 Deka Products Limited Partnership Pump chamber configured to contain a residual fluid volume for inhibiting the pumping of a gas
US7153425B2 (en) * 1999-09-17 2006-12-26 Entegris, Inc. Process and filter for filtering a slurry
US7247245B1 (en) * 1999-12-02 2007-07-24 Entegris, Inc. Filtration cartridge and process for filtering a slurry
US20110044866A1 (en) * 2000-03-22 2011-02-24 Dewalch Norman Binz Method and Apparatus for Processing Substances in a Single Container
US20080260593A1 (en) * 2000-03-22 2008-10-23 Dewalch Norman Binz Method and apparatus for processing substances in a single container
US6497685B1 (en) 2000-03-24 2002-12-24 Baxter International Inc. Integral intravenous chamber and filter
US20020120224A1 (en) * 2001-01-31 2002-08-29 Majid Zia Multi-purpose tubing apparatus
US20090270837A1 (en) * 2001-01-31 2009-10-29 Majid Zia Multi-purpose tubing apparatus
US8640738B2 (en) 2001-01-31 2014-02-04 Haemonetics Corporation Multi-purpose tubing apparatus
US7571744B2 (en) 2001-01-31 2009-08-11 Hemerus Medical, Llc Multi-purpose tubing apparatus
US20020143298A1 (en) * 2001-03-30 2002-10-03 Becton, Dickinson And Company Blunt cannula and filter assembly and method of use with point-of-care testing cartridge
US6869405B2 (en) 2001-03-30 2005-03-22 Becton, Dickinson And Company Blunt cannula and filter assembly and method of use with point-of-care testing cartridge
US20070037132A1 (en) * 2001-05-07 2007-02-15 Sivaprasad Sukavaneshvar Separation of platelets from fluid suspensions
US20060127875A1 (en) * 2001-05-07 2006-06-15 Sivaprasad Sukavaneshvar Device for separation of platelets from whole blood
US8101077B2 (en) 2001-05-07 2012-01-24 Sivaprasad Sukavaneshvar Device for separating platelets from fluid suspensions
US7060181B2 (en) 2001-11-07 2006-06-13 Tetra Holding (Us), Inc. Dual density filter cartridge
US6692637B2 (en) * 2001-11-07 2004-02-17 Tetra Holding (Us), Inc. Dual density filter cartridge
US20040159598A1 (en) * 2001-11-07 2004-08-19 Tetra Holding (Us), Inc. Dual density filter cartridge
US20040238426A9 (en) * 2001-11-07 2004-12-02 Tetra Holding (Us), Inc. Dual density filter cartridge
US20030085167A1 (en) * 2001-11-07 2003-05-08 Fox John Edward Dual density filter cartridge
US20060180534A1 (en) * 2001-11-07 2006-08-17 Tetra Holding (Us), Inc. Dual density filter cartridge
US9283065B2 (en) 2003-11-12 2016-03-15 Nitinol Devices And Components, Inc. Medical device anchor and delivery system
US8398672B2 (en) 2003-11-12 2013-03-19 Nitinol Devices And Components, Inc. Method for anchoring a medical device
US8409239B2 (en) 2003-11-12 2013-04-02 Nitinol Devices And Components, Inc. Medical device anchor and delivery system
US7063685B2 (en) * 2004-05-12 2006-06-20 C. R. Bard, Inc. Hemostasis valve for a catheter
US8177760B2 (en) 2004-05-12 2012-05-15 C. R. Bard, Inc. Valved connector
US20050256460A1 (en) * 2004-05-12 2005-11-17 Guy Rome Valved connector
US20080147012A1 (en) * 2004-05-12 2008-06-19 C.R.Bard, Inc. Catheter with Removable Extension
US20050256457A1 (en) * 2004-05-12 2005-11-17 Guy Rome Hemostasis valve for a catheter
US8337700B1 (en) * 2005-02-24 2012-12-25 Hemerus Medical, Llc High capacity biological fluid filtration apparatus
US7837875B2 (en) 2005-08-31 2010-11-23 Eaton Corporation Fluid filter
US20070108117A1 (en) * 2005-08-31 2007-05-17 Wim Callaert Fluid filter
US9649211B2 (en) 2009-11-04 2017-05-16 Confluent Medical Technologies, Inc. Alternating circumferential bridge stent design and methods for use thereof
US10092427B2 (en) 2009-11-04 2018-10-09 Confluent Medical Technologies, Inc. Alternating circumferential bridge stent design and methods for use thereof
US9833748B2 (en) 2010-08-25 2017-12-05 Lockheed Martin Corporation Perforated graphene deionization or desalination
US20120219633A1 (en) * 2011-02-28 2012-08-30 Pall Corporation Removal of immunoglobulins and leukocytes from biological fluids
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
US10201784B2 (en) 2013-03-12 2019-02-12 Lockheed Martin Corporation Method for forming perforated graphene with uniform aperture size
US9572918B2 (en) 2013-06-21 2017-02-21 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
US10471199B2 (en) 2013-06-21 2019-11-12 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
US9870895B2 (en) 2014-01-31 2018-01-16 Lockheed Martin Corporation Methods for perforating two-dimensional materials using a broad ion field
US9744617B2 (en) 2014-01-31 2017-08-29 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
US10500546B2 (en) 2014-01-31 2019-12-10 Lockheed Martin Corporation Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
US9844757B2 (en) 2014-03-12 2017-12-19 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US9610546B2 (en) 2014-03-12 2017-04-04 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US10005038B2 (en) 2014-09-02 2018-06-26 Lockheed Martin Corporation Hemodialysis and hemofiltration membranes based upon a two-dimensional membrane material and methods employing same
US10418143B2 (en) 2015-08-05 2019-09-17 Lockheed Martin Corporation Perforatable sheets of graphene-based material
US10696554B2 (en) 2015-08-06 2020-06-30 Lockheed Martin Corporation Nanoparticle modification and perforation of graphene
US10376845B2 (en) 2016-04-14 2019-08-13 Lockheed Martin Corporation Membranes with tunable selectivity
US10213746B2 (en) 2016-04-14 2019-02-26 Lockheed Martin Corporation Selective interfacial mitigation of graphene defects
US10203295B2 (en) 2016-04-14 2019-02-12 Lockheed Martin Corporation Methods for in situ monitoring and control of defect formation or healing
US10118130B2 (en) 2016-04-14 2018-11-06 Lockheed Martin Corporation Two-dimensional membrane structures having flow passages
US10017852B2 (en) 2016-04-14 2018-07-10 Lockheed Martin Corporation Method for treating graphene sheets for large-scale transfer using free-float method
US10981120B2 (en) 2016-04-14 2021-04-20 Lockheed Martin Corporation Selective interfacial mitigation of graphene defects
US10980919B2 (en) 2016-04-14 2021-04-20 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials
CN110799225A (en) * 2017-06-10 2020-02-14 费森尤斯医疗护理德国有限责任公司 Device for extracorporeal blood treatment and device for collecting blood clots and method for determining hemodynamic parameters during extracorporeal blood treatment
US11612683B2 (en) 2018-07-24 2023-03-28 Healeon Llc Device and method for resizing adipose and other tissues for implantation
US11672899B2 (en) * 2018-07-24 2023-06-13 Healeon Llc Device and method for resizing adipose tissue for implantation
WO2022066664A1 (en) * 2020-09-23 2022-03-31 Carefusion 303, Inc. Intravenous filter
US11672908B2 (en) 2020-09-23 2023-06-13 Carefusion 303, Inc. Intravenous filter

Also Published As

Publication number Publication date
GB1242493A (en) 1971-08-11
DE1928052A1 (en) 1970-12-10
FR2048130A5 (en) 1971-03-19

Similar Documents

Publication Publication Date Title
US3593854A (en) Blood treating and filtering apparatus
US3448041A (en) Method and apparatus for treating blood preliminary to its use in transfusions
US5744047A (en) Leucocyte depleting filter device and method of use
US4115277A (en) Blood filtering apparatus of graduated fiber density
ES2249538T3 (en) DEVICE AND METHOD FOR EXHAUSTING THE CONTENT OF LEUKOCYTES OF BLOOD COMPONENTS.
JP2523938B2 (en) Platelet purification filter
US4116845A (en) High capacity blood transfusion micro filter
US5540841A (en) Cardioplegia filter and method for processing cardioplegia fluid
JPH06506365A (en) Method and device for removing non-soluble fat from patient's blood
JPS5883968A (en) Microfilteration apparatus of coagulated blood and blood components
KR100392315B1 (en) Filter Device and Method for Processing Blood
CA2047943C (en) Leucocyte depleting filter device and method of use
JPH05345020A (en) Device and method for detecting hemolysis
JPS59207139A (en) Defoaming/filtering/resorvoir apparatus
CA2261612A1 (en) Method for removing tumor cells from tumor cell-contaminated stem cell products
US3770129A (en) Manually flexible blood filter
EP0887098B1 (en) Gas plasma treated porous medium and method of separation using same
JP5164241B2 (en) Blood treatment filter device
EP0728491B1 (en) Method of producing a blood transfusion device
US4944884A (en) Body fluid purification method using activated carbon fibers of novoloid resin origin
JP2918595B2 (en) White blood cell separator
JPH0510105B2 (en)
JPS6350021B2 (en)
AU2010205520B2 (en) Extracorporeal blood filtration
JPH067432A (en) Blood constituent separating apparatus

Legal Events

Date Code Title Description
PS Patent suit(s) filed
AS Assignment

Owner name: COBE LABORATORIES, INC., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOC GROUP, INC. THE A CORP. OF DE;REEL/FRAME:004547/0546

Effective date: 19860430

Owner name: COBE LABORATORIES, INC., 1201 OAK STREET, LAKEWOOD

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:BOC GROUP, INC. THE A CORP. OF DE;REEL/FRAME:004547/0546

Effective date: 19860430

AS Assignment

Owner name: PIONEER VIGGO INC., 5490 BROADWAY, LANCASTER, NEW

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST. SUBJECT TO CONDITIONS RECITED;ASSIGNOR:SWANK, ROY L.;REEL/FRAME:004583/0391

Effective date: 19771005

Owner name: PIONEER VIGGO INC.,NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SWANK, ROY L.;REEL/FRAME:004583/0391

Effective date: 19771005